Aclarion, Inc. (ACON) stock
Close on Nov 11, 2026Market cap $4.70MP/E –Yield –
Aclarion, Inc. grew revenue 46.0% to $98.56K over the twelve months to Sep 30, 2026. Free cash flow was -$7.19M. At the latest close the market valued the company at $4.70M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $4.70M
- P/E ratio
- –
- Price to sales
- 47.67
- Price to book
- 0.32
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $98.56K
- Net income
- -$10.11M
- EPS, diluted
- -$13.61
- Free cash flow
- -$7.19M
- Book value per share
- $5.33
- Diluted shares
- 3M
Trading
- Previous close
- $1.60
- Open
- $1.64
- Day's range
- $1.54 – $1.64
- Volume
- 26,874
- Average volume (20 days)
- 14,920
- Beta (5 years)
- 0.77
- 52-week range
- $1.54 – $9.36
- RSI (14 days)
- 35.0
- Volatility (1 year)
- 94.6%
- Relative volume
- 0.62×
- WACC
- 8.7%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ACON | S&P 500 | Difference | ACON per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.3% | -2.4% | −27.9 pts | ||
| 3 months | -28.5% | -1.2% | −27.4 pts | ||
| Year to date | -64.6% | +12.3% | −76.9 pts | ||
| 1 year | -77.2% | +12.4% | −89.6 pts | ||
| 3 years | -100.0% | +78.8% | −178.8 pts | -96.8% | +21.4% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aclarion filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Update
- Update
- Update
- Update
About Aclarion
Services-Medical Laboratories
Aclarion, Inc. is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy and proprietary biomarkers to enhance clinical treatments for back and neck pain. Its proprietary software transforms spectroscopy signal data into biomarkers to help determine whether an intervertebral disc is a source of chronic pain. The company primarily targets chronic discogenic low back pain by assisting spine surgeons in selecting optimal surgical interventions.
Company profile, executives and historyAclarion stock: common questions
What is Aclarion's stock price?
ACON closed at $1.63 on Nov 11, 2026, up 1.87% on the day. Over the past 52 weeks it traded between $1.54 and $9.36.
What is Aclarion's market cap?
Aclarion was worth $4.70M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ACON's P/E ratio?
Aclarion lost money over fiscal 2025 (diluted EPS -$13.61), so it has no meaningful P/E ratio.
How much revenue does Aclarion make?
Aclarion reported revenue of $98.56K for the twelve months to Sep 30, 2026, up 46.0% from a year earlier.
Does Aclarion pay a dividend?
No. Aclarion has not paid a cash dividend over the last twelve months.
How has ACON stock performed over the past year?
Including dividends, ACON returned -77.2% over the past year, against +12.4% for the S&P 500.
Who are Aclarion's competitors?
Companies most similar to Aclarion by business, industry and size include SERA, ADVB, YDES, BRTX, PFSA.
See a number that looks wrong?